We are thrilled to announce the rekindling of connections between the neuroblastoma research teams in Ghent and Berlin! By joining forces once again, we aim to foster innovative research, exchange…
Bij veel soorten (kinder)kanker zijn normale ontwikkelprocessen verstoord. De factoren die hierin een rol spelen worden gezien als mogelijke doelwitten voor effectievere en minder toxische behandelingen. Er wordt daarom veel…
The pediatric extra-cranial tumor neuroblastoma displays a low mutational burden while recurrent copy number alterations are present in most high-risk cases. Here, we identify SOX11 as a dependency transcription factor…
To inhibit or to degrade? For certain cancer drug targets, like Aurora Kinase A (AURKA), protein degradation may be beneficial and offer a more targeted-therapeutic approach compared to the use…
Onderzoekers van de vakgroep Biomoleculaire Geneeskunde hebben ontdekt hoe patiënten een hoog-risico neuroblastoom ontwikkelen. Door twee bestaande medicijnen te combineren, zou deze vorm van kinderkanker in de toekomst beter behandeld…
Want to know more on how copy number changes shape neuroblastoma biology, check out our new review in the latest issue of Journal of Personalized Medicine: “From DNA Copy Number Gains…
MEIS2 Is an Adrenergic Core Regulatory Transcription Factor Involved in Early Initiation of TH-MYCN-Driven Neuroblastoma Formation. Our discovery efforts focused on identifying cooperating interactors and vulnerabilities in the MYCN regulatory network. MYCN-driven neuroblastomas can…
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkNoPrivacy policy